Vireo Growth (VREOF) Enterprise Value (2020 - 2026)
Vireo Growth (VREOF) posted Enterprise Value of -$153.2 million for Q1 2026, down 7.28% sequentially from -$142.8 million in Q4 2025, and down 74.19% YoY from -$593.5 million in Q1 2025.
Vireo Growth (VREOF) Enterprise Value (2020 - 2026) Analysis & Trends
Vireo Growth has reported Enterprise Value for 7 years, with the latest figure at -$153.2 million in Q1 2026.
- Quarterly Enterprise Value fell 74.19% year-over-year to -$153.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$153.2 million (down 74.19% YoY) and the FY2025 annual result came in at -$142.8 million, down 52.12% from the prior year.
- Enterprise Value eased to -$153.2 million in Q1 2026 per VREOF's latest filing, from -$142.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$7.3 million in Q3 2024 and troughed at -$153.2 million in Q1 2026.
- A 5-year average of -$49.6 million and a median of -$17.0 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value soared 78.79% in 2022, then slumped 1528.49% in 2025.
- Over 5 years, Enterprise Value stood at -$15.1 million in 2022, then retreated by 18.17% to -$17.9 million in 2023, then sank by 424.36% to -$93.9 million in 2024, then tumbled by 52.12% to -$142.8 million in 2025, then dropped by 7.28% to -$153.2 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$153.2 million, -$142.8 million, and -$118.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | -882.82 Mn |
| 2 | Teva Pharmaceutical Industries | 43.01 Bn | 39.35 Bn | 2.15 Bn | -3.65 Bn |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | -1.68 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -5.79 Bn |
| 5 | United Therapeutics | 22.17 Bn | 19.51 Bn | 683.80 Mn | -2.66 Bn |
| 6 | Viatris | 18.73 Bn | 17.85 Bn | 1.46 Bn | -886.50 Mn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | -389.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | -164.00 Mn |
| 10 | Vireo Growth | 482.88 Mn | 340.58 Mn | 95.30 Mn | -142.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -153.20 Mn |
| Dec 31, 2025 | -142.80 Mn |
| Sep 30, 2025 | -118.55 Mn |
| Jun 30, 2025 | -100.41 Mn |
| Mar 31, 2025 | -87.95 Mn |
| Dec 31, 2024 | -93.87 Mn |
| Sep 30, 2024 | -7.28 Mn |
| Jun 30, 2024 | -11.23 Mn |
| Mar 31, 2024 | -12.60 Mn |
| Dec 31, 2023 | -17.90 Mn |
| Sep 30, 2023 | -13.30 Mn |
| Jun 30, 2023 | -11.35 Mn |
| Mar 31, 2023 | -10.35 Mn |
| Dec 31, 2022 | -15.15 Mn |
| Sep 30, 2022 | -21.84 Mn |
| Jun 30, 2022 | -16.97 Mn |
| Mar 31, 2022 | -8.60 Mn |
| Dec 31, 2021 | -15.16 Mn |
| Sep 30, 2021 | -11.78 Mn |
| Jun 30, 2021 | -20.83 Mn |